Abstract Library

#4622 Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours

Introduction: We have recently demonstrated that HMGB3 is upregulated during the pancreatic neuroendocrine tumours (PanNETs) transition via dedifferentiation from a relatively benign molecular subtype to an aggressive and highly metastatic molecular subtype. HMGB3 expression has recently been linked to resistance to therapy, metastasis, and poor prognosis in patients with various solid cancers.

Conference:

Presenting Author: Kulathunga N

Authors: Kulathunga N, Wang Z, Qureshi A, Lok B, Tyryshkin K,

Keywords: pancreatic neuroendocrine tumour, HMGB3, tumour progression,

#4607 BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs

Introduction: There is an unmet clinical need to identify new, effective therapies for patients with neuroendocrine tumours (NETs). Analysis of single-cell expression data revealed that NETs express high levels of the Bcl2 family of antiapoptotic proteins. Therefore, we hypothesised that proapoptotic drugs, such as BH3-mimetics, can induce programmed cell death, i.e., apoptosis, of neuroendocrine cancer cells.

Conference:

Presenting Author: Michael I

Authors: Kulathunga N, Wang Z, Kale J, Lens A, Tsui H,

Keywords: neuroendocrine tumour, BH3-mimetics, Navitoclax, Cabozantinib, patient-derived organoids, apoptosis, 177Lu-Dotatate,

#4550 The relationship between MEN1 germline mutations and SSTR2 expression in neuroendocrine tumours

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary disease characterised by the development of multiglandular parathyroid disease, pituitary tumours, and duodenopancreatic neuroendocrine tumours (NETs). Germline mutations in the tumour suppressor gene MEN1 are the underlying cause. Somatostatin receptor 2 (SSTR2) is commonly expressed by NETs. However, the expression of SSTR2 in patients with MEN1 remains unclear.

Conference:

Presenting Author: Chi Y

Authors: Sun Y, Tan H, Wang H, Shi S, Dong L,

Keywords: multiple endocrine neoplasia type 1, somatostatin receptor 2, neuroendocrine tumour,

#4526 The relationship between adherence to traditional Chinese medicine and disease progression in type 1 gastric neuroendocrine tumours: A case report

Introduction: Type 1 gastric neuroendocrine tumours (g-NETs) have a high recurrence risk after endoscopic resection, underscoring the need for regular endoscopic follow-up. Our research hints that Traditional Chinese Medicine (TCM) could help lower recurrence rates.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Cheng Z, Yu F, Chen R, Chen X,

Keywords: type 1 gastric neuroendocrine tumour, Traditional Chinese Medicine, regular follow-up, case report,

#4525 MRI findings of jejunal mesentery neuroendocrine tumour – A case report

Introduction: Neuroendocrine tumours arising from the mesentery are uncommon, with corresponding MRI features infrequently documented in the literature.

Conference:

Presenting Author:

Authors: Guo L, Li Z, Yang H, Dong H, Wang Y,

Keywords: Magnetic Resonance Imaging, Jejunal Mesentery, Neuroendocrine Tumour, Diagnosis,